04:03:15 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-02-28 Bokslutskommuniké 2022
2023-02-09 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning RLS 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-07-16 Kvartalsrapport 2021-Q2
2021-06-17 Årsstämma 2021
2021-05-27 Ordinarie utdelning RLS 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-10 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning RLS 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-19 Extra Bolagsstämma 2019
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning RLS 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-30 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-06-14 Ordinarie utdelning RLS 0.00 SEK
2018-06-13 Årsstämma 2018
2018-05-31 Kvartalsrapport 2018-Q1
2018-02-28 Bokslutskommuniké 2017
2017-11-28 Kvartalsrapport 2017-Q3
2017-11-15 Extra Bolagsstämma 2017
2017-08-31 Kvartalsrapport 2017-Q2
2017-06-09 Ordinarie utdelning RLS 0.00 SEK
2017-06-08 Årsstämma 2017
2017-05-31 Kvartalsrapport 2017-Q1
2017-02-20 Bokslutskommuniké 2016
2016-11-30 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2
2016-06-01 Ordinarie utdelning RLS 0.00 SEK
2016-05-31 Årsstämma 2016
2016-05-31 Kvartalsrapport 2016-Q1
2016-02-29 Bokslutskommuniké 2015
2016-01-21 Extra Bolagsstämma 2016
2015-11-30 Kvartalsrapport 2015-Q3
2015-08-31 Kvartalsrapport 2015-Q2
2015-06-12 Ordinarie utdelning RLS 0.00 SEK
2015-06-11 Årsstämma 2015
2015-05-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-11-28 Kvartalsrapport 2014-Q3
2014-09-12 Extra Bolagsstämma 2014
2014-08-29 Kvartalsrapport 2014-Q2
2014-06-10 Ordinarie utdelning RLS 0.00 SEK
2014-06-09 Årsstämma 2014
2014-05-23 Kvartalsrapport 2014-Q1
2014-03-05 Bokslutskommuniké 2013
2013-11-29 Kvartalsrapport 2013-Q3
2013-09-04 Kvartalsrapport 2013-Q2
2013-05-31 Kvartalsrapport 2013-Q1
2013-05-08 Split RLS 10:1
2013-04-11 Ordinarie utdelning RLS 0.00 SEK
2013-04-10 Årsstämma 2013
2013-03-05 Bokslutskommuniké 2012
2012-11-26 Kvartalsrapport 2012-Q3
2012-08-31 Kvartalsrapport 2012-Q2
2012-06-12 Ordinarie utdelning RLS 0.00 SEK
2012-06-11 Årsstämma 2012

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
RLS Global är verksamma inom bioteknik. Bolaget utvecklar biokemiska produkter och metoder för behandling av förekommande sår hos patienter. Bolagets produkter angriper skadad vävnad via den egenutvecklade teknologin som baseras på hypoklorit. Idag bedrivs forskning och utveckling inom vävnadsbaserad teknik. Bolaget har sitt huvudkontor i Göteborg.
2022-08-11 09:00:00

During the last six months, RLS Global and ConvaTec have worked in close collaboration to collect clinical experiences of ChloraSolv from three different wound centers in the UK. Six case studies have been compiled into a report and published as a supplement in Journal of Wound Care, issue no 7 2022 (https://www.magonlinelibrary.com/page/jowc/resources). The aim is to demonstrate the implementation of ChloraSolv in practice.

The clinical experience shows that ChloraSolv has strong debridement efficacy, as well as good safety and ease of use. It means that the technology can be used by any health care professional involved in wound care, regardless of their skills and experience. Therefore, it can easily be incorporated into all wound management pathways.

In total 30 patients were treated with ChloraSolv. Most of the patients in the case studies were previously unable to tolerate debridement due to the pain and discomfort it caused them, which greatly impaired healing. This has had a significant negative effect on their quality of life. The gentle action of ChloraSolv made the debridement acceptable and tolerable to the patient.

"RLS Global continues to work in close collaboration with ConvaTec to collect clinical data and experience of ChloraSolv. This is the first published report sharing data of the implementation of ChloraSolv in practice. We are of course very satisfied with the outcome and the fact that Journal of Wound Care is publishing the supplement", says Karin Fischer, CEO, RLS Global.

"The conclusion that ChloraSolv can be used by all health care professionals and is gentle and efficient for the patients has a significant impact on the treatment of hard to heal wounds, from a health economic perspective".

Click to find full supplement. (https://www.magonlinelibrary.com/pb-assets/JOWC/ConvaTec_ChloraSolv-1658917969800.pdf)

THIS IS CHLORASOLV
ChloraSolv is a wound debridement gel, based on a unique hypochlorite technology, which is used with very good effect on hard-to-heal leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.[1] ChloraSolv does not damage healthy tissue and is well tolerated by the patient.

1. Eliasson B, Fagerdahl AM, Jönsson A, Apelqvist J. An open single arm multicenter pilot investigation to evaluate the debriding effect of amino acid buffered hypochlorite (ChloraSolv®) on chronic wounds covered with devitalized tissue during six weeks treatment. Journal of Wound Care (Accepted for publication).